Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has shared an announcement.
GenFleet Therapeutics reported that its extraordinary general meeting in Shanghai on February 9, 2026, was duly convened with all directors present and voting conducted by poll under Hong Kong Listing Rules. The meeting confirmed that all issued shares carried voting rights, with no treasury or restricted shares affecting turnout, and Computershare Hong Kong acted as scrutineer to validate the results.
Shareholders approved a suite of capital and governance measures, including an H share option scheme, an H share incentive scheme with an overall limit and service provider sublimit, and a share repurchase mandate for the board. The EGM also backed amendments to the articles of association and the abolition of the supervisory committee, signalling a shift in GenFleet’s governance structure that may streamline decision-making and align it more closely with international corporate practices.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company listed in Hong Kong that focuses on developing innovative therapies, with its share capital divided into H shares and unlisted shares. The company operates under PRC corporate law and Hong Kong Listing Rules, reflecting a cross-border capital markets orientation and an investor base spanning both public and institutional shareholders.
Average Trading Volume: 748,470
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$11.64B
See more data about 2595 stock on TipRanks’ Stock Analysis page.